Circulation:亚临床甲状腺功能减退与心房颤动风险之间相关性分析!

2017-10-27 xing.T MedSci原创

由此可见,在甲状腺功能正常的个体中,较高的循环FT4水平,而不是TSH水平,与增加的AF发生风险相关。

房颤动(AF)是一种非常流行的疾病,可以导致心力衰竭、卒中和死亡。加强对可改变危险因素的了解,才能有机会预防AF。亚临床甲状腺功能亢进症会导致房颤的风险增加,但在正常范围或亚临床甲状腺功能减退是否也与房颤有关尚不明确。近日,心血管领域权威杂志Circulation上针对这一问题发表了一篇研究文章。

研究人员进行了一项系统评价,并从测定了基础甲状腺功能和评估了AF发生的前瞻性队列研究中得到了个体参与者数据,这些研究是从MEDLINE和EMBASE数据库中确定的,检索时间从这些数据库成立到2016年7月27日截止。甲状腺功能正常被定义为促甲状腺激素(TSH)为0.45至4.49mIU/L,亚临床甲减被定义为TSH为4.5至19.9mIU/L和游离甲状腺素(FT4)水平在正常范围内。研究人员采用Cox比例风险模型分析了TSH水平在正常范围和亚临床甲减范围与AF之间的相关性。在甲状腺功能正常的参与者中,研究人员还评估了FT4水平和AF发生之间的关联。

纳入分析的11个队列共有30085名参与者(278955人次每年随访),1958名(6.5%)亚临床甲状腺功能减退症患者,2574名(8.6%)患者在随访期间出现房颤。基础TSH水平与AF的发生在甲状腺功能正常的参与者或是亚临床甲状腺功能减退症患者中并无显著相关性。在甲状腺功能正常的个体基础FT4水平较高在调整了年龄和性别与增加的AF风险相关(风险比为1.45;95%可信区间为1.26-1.66,FT4最高四分位与最低四分位数相比,趋势P≤0.001)。在对已有心血管疾病的受试者进行进一步调整后,估计值没有较大的差异。

由此可见,在甲状腺功能正常的个体中,较高的循环FT4水平,而不是TSH水平,与增加的AF发生风险相关。

原始出处:

Christine Baumgartner,et al. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism and the Risk of Atrial Fibrillation. Circulation. 2017. https://doi.org/10.1161/CIRCULATIONAHA.117.028753

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837363, encodeId=192a183e3636a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 28 19:24:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523550, encodeId=ec55152355038, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626855, encodeId=3309162685551, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797429, encodeId=899f1e974297d, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Jan 20 02:24:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837363, encodeId=192a183e3636a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 28 19:24:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523550, encodeId=ec55152355038, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626855, encodeId=3309162685551, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797429, encodeId=899f1e974297d, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Jan 20 02:24:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837363, encodeId=192a183e3636a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 28 19:24:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523550, encodeId=ec55152355038, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626855, encodeId=3309162685551, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797429, encodeId=899f1e974297d, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Jan 20 02:24:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
    2017-10-28 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837363, encodeId=192a183e3636a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Jun 28 19:24:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523550, encodeId=ec55152355038, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626855, encodeId=3309162685551, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Oct 28 22:24:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797429, encodeId=899f1e974297d, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Jan 20 02:24:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]

相关资讯

重复:N Engl J Med:左旋甲状腺素对亚临床甲减老年患者或是无用的治疗

亚临床甲状腺功能减退患者是否应接受左旋甲状腺激素治疗仍存在争议。2017年6月,发表在《N Engl J Med》上的一项研究显示,左旋甲状腺素未给亚临床甲状腺功能减退老年患者提供明显益处。

总结: 亚临床甲状腺功能减退的危害及治疗

作者:第四军医大学西京医院  姬秋和  蔡靖 目前,关于亚临床甲状腺功能减退(SCH),国内外已出台多部指南,如2013年欧洲甲状腺学会(ETA)《成人亚临床甲状腺功能减退指南》、2014年ETA《妊娠与儿童亚临床甲状腺功能减退指南》、2012年中华医学会内分泌学分会和围产医学分会《妊娠和产后甲状腺疾病诊治指南》及2011年美国甲状腺学会《妊娠和产后甲状